Stanford researchers have developed EphrinA3 technology to strengthen epithelial barriers by increasing expression of cell-cell adhesion molecules, particularly desmoglein-1 (DSG1) and desmocollin-1 (DSC1).
Researchers at Stanford have developed a microparticle-based vaccine that in a single shot enables enhanced activation of CD8+ and/or CD4+ T cells to fight against infectious diseases and cancer.